medigraphic.com

2011, Number 4

<< Back Next >>

Rev Hematol Mex 2011; 12 (4)

Acute myelogenous leukemia: A perspective

Cáceres-Cortés JR

Language: English
References: 54
Page: 257-266
PDF size: 132.93 Kb.


ABSTRACT

Acute myeloblastic leukaemia is characterized by the extreme clonal proliferation of haematopoietic precursor cells with abnormal or arrested differentiation. Chemotherapy of acute leukaemia is channelled towards the reduction and eradication of leukaemic cells. However, relapse is generally assumed to occur in residual host cells, which are refractory to or elude therapy. The cancer stem cell hypothesis has gained considerable importance in recent years and could interpret this behaviour. This persuasive theory states that cells within a tumour are organized in a hierarchy similar to that of normal tissues, and are maintained by a small subset of cells responsible for tumour dormancy. These cells, defined as «tumour initiating cells» (TICs), possess several properties of normal tissue stem cells. Recently, the TICs associated with AML have been shown to comprise distinct, hierarchically arranged classes similar to those observed for haematopoietic stem cells. We know now that the growth and survival of blasts in AML are driven by the same growth factors that stimulate normal cells. Furthermore, direct evidence of the role of membrane steel factor and its receptor c-Kit in cell-cell interactions and cell survival in primary AML blasts has been provided, defining the importance of juxtacrine stimulation. Inhibition of c-Kit signaling induces combinations of cell death: autophagy (compensatory mechanism toward survival) and apoptosis. While recent work confirmed that c-Kit inhibitors reduce cancer cell proliferation, it also demonstrated that future inappropriate prescriptions could cause normal tissue deterioration. The purpose of this paper was to review some of the salient features of leukaemic blasts in support of the proposal that research into neoplasia be increased. Rather than presenting the details of various studies, I have attempted to indicate general areas in which work has been done or is in progress. It is hoped that this survey of the subject will demonstrate a variety of opportunities for additional research in human neoplasia.


REFERENCES

  1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907

  2. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008;49:388-397.

  3. Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19:301-319.

  4. Linet MS, Devesa SS. Descriptive epidemiology of the leukemias. In: Henderson ES, Lister TA eds. Leukemia, 5 rd ed. Cancer Facts and Figures. Atlanta, American Cancer Society, 1991;1-31

  5. Wiernik PH. Acute leukemias. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3 rd ed. Philadelphia: JB Lippincott Company, 1989;1809-1835.

  6. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Gómez-Rangel JD, Ruiz-Delgado GJ. More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 2004;45:1365-1368.

  7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011

  8. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011;2:95-107.

  9. Brunning RD. Classification of acute leukemias. Semin Diagn Pathol 2003;20:142-153.

  10. Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA. New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. Discov Med 2010;10:281-292.

  11. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71()/HLA-DR. Blood 1998;92:4325-4335

  12. Moore CV. Natural history and diagnostic peculiarities of acute leukemia. Cancer J Clin 1964;14:204-209.

  13. Russell NH. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev 1992;6:149-156.

  14. Forman SJ. What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Hematology Am Soc Hematol Educ Program 2009:406-413.

  15. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010;10:425-434.

  16. Lawler M, Locasciulli A, Longoni D, Schiro R, McCann SR. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant 2002;29:453-456.

  17. McCulloch EA, Minkin S, Curtis JE, Minden MD. Response of the blast stem cells of acute myeloblastic leukemia to G-CSF, GM-CSF, or the ligand for C-KIT, alone or in combination. Hematopathol Mol Hematol 1996;10:111-122.

  18. Cáceres-Cortés JR, Hoang T. Product of the Steel locus can replace leukemic cell interaction. Cancer Res 1992;52:5208-5212.

  19. Cáceres-Cortes JR, Alvarado-Moreno JA, Waga K, Rangel- Corona R, Monroy-Garcia A, et al. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res 2001;61:6281-6289.

  20. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992;80:60-67.

  21. Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 1996;95:257-262.

  22. Zheng R, Klang K, Gorin NC, Small D. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk Res 2004;28:1241.

  23. Greenberger JS. Ras mutations in human leukemia and related disorders. Int J Cell Cloning 1989;7:343-359.

  24. Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 2009;4:77-82.

  25. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75:93-109.

  26. Caceres-Cortes JR. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem 2008;8:717-722.

  27. Lara-Padilla E, Cáceres-Cortés JR. On the nature of the tumor-initiating cell. Current stem cell research and therapy. In Press, 2011.

  28. Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-5291.

  29. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.

  30. Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 2005;48:1359-1366.

  31. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. PLoS One. 2009;4:e7258.

  32. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-3919.

  33. Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 2006;66:1015-1024.

  34. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-255.

  35. Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27:4169-4176.

  36. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-322.

  37. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006;86:1203-1207.

  38. Killmann SA. Preleukemia: does it exist? Nouv Rev Fr Hematol Blood Cells 1976;17:81-105.

  39. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.

  40. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 2005;82:389-396.

  41. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.

  42. Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma 2005;52:435-440.

  43. Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in cancer cell lines. Cell Cycle 2004;3:414-415.

  44. Liang C, Feng P, Ku B, Dotan I, et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol 2006;8:688-699.

  45. Watson AS, Mortensen M, Simon AK. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle 2011;10:1719-1725.

  46. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) 2011;89:221-228.

  47. Chiacchiera F, Simone C. Signal-dependent control of autophagyrelated gene expression. Methods Enzymol 2009;453:305-324.

  48. Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007;14:548-558.

  49. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500-510.

  50. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006;16:60-64.

  51. Tajbakhsh S, Rocheteau P, Le Roux I. Asymmetric cell divisions and asymmetric cell fates. Annu Rev Cell Dev Biol 2009;25:671-699.

  52. Singer BH, Pincus S. Irregular arrays and randomization. Proc Natl Acad Sci 1998;95:1363-1368.

  53. Mendoza-Rincon JF, González-Robles A, Lopez-Marure R, Caceres-Cortes JR. Enhanced activity of pSTAT-3 Ser-727 in functional endothelial cells under calcifying conditions. Curr Chem Biol 2010;4:133-144.

  54. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011;10:1533-1541.




2020     |     www.medigraphic.com